Author:
Tu Hung-Pin,Lan Cheng-CheE,Yu Sebastian,Tsao Yu-Hsiang
Reference40 articles.
1. The problem of choice: Current biologic agents and future prospects in RA;Choy;Nat Rev Rheumatol,2013
2. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial;Ritchlin;Ann Rheum Dis,2014
3. Changes in metabolic parameters in psoriasis patients treated with interleukin-12/23 blockade (ustekinumab);Ng;Dermatol Sin,2020
4. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction;Papp;Br J Dermatol,2005
5. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial;Menter;J Am Acad Dermatol,2008
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献